For children with hemophilia A, the FDA has accepted the sBLA for ALTUVIIIO.

Published Date: 17 Sep 2023

The FDA has approved a supplemental biologics license application for ALTUVIIIO (Antihemophilic factor; Sanofi) for use in patients with severe hemophilia A who are 12 years of age or younger.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reducing social media to an hour a day boosts young people's self-image.

2.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

3.

The pandemic had little impact on mental health symptoms.

4.

FDA Approves New Bladder Cancer First-Line Standard of Care.

5.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot